Alimentary Pharmacology & Therapeutics
First published: 27 June 2017
DOI: 10.1111/apt.14203
Y. Derwa,D. J. Gracie, P. J. Hamlin, A. C. Ford
Background: Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis.
Aim: To perform a systematic review and meta-analysis to examine the efficacy of probiotics in IBD.
Methods: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (until November 2016). Eligible randomised controlled trials (RCTs) recruited adults with UC or CD, and compared probiotics with 5-aminosalicylates (5-ASAs) or placebo. Dichotomous symptom data were pooled to obtain a relative risk (RR) of failure to achieve remission in active IBD…
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.